InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: gestalt2 post# 5636

Sunday, 08/28/2016 4:58:34 PM

Sunday, August 28, 2016 4:58:34 PM

Post# of 233563
It needs an uplist to the NASDAQ IMO. Considering that it is in two phase 3 trials It should uplist. Most other small cap biotechs uplist with only phase 2 trials in process. I don't predict it will move much if they don't uplist. Either that or results of phase 3 come out. But phase 3 results for the adjunct therapy should take until July 2017 to September 2017 IMO. So at least one year, because they added the 100 patients for placebo control.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News